Travere Therapeutics (TVTX) is up 32.5%, or $9.99 to $40.69.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $44 from $39 at Wedbush
- Travere Therapeutics up 43% in premarket at $43.81 on FDA approval for Filspari
- Travere Therapeutics price target raised to $54 from $49 at Guggenheim
- Ligand price target raised to $250 from $244 at BofA
- Travere Therapeutics price target raised to $49 from $44 at BofA